SVF
Insufficient· Insufficient EvidenceNarrative Review

Mesenchymal Stem Cells Derived Extracellular Vesicles in Inflammatory Bowel Disease: Therapeutic Efficacy and Bioengineering Applications.

Li Z., Sun Y., Wu J., Zhang W., Li T., Tang S.

Narrative Review on Chronic Inflammation, Immune Modulation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Nanomedicine (2026)
Country
New Zealand
Reported sample size
—
PMID
41993781
DOI
10.2147/IJN.S584494

Abstract (original English)

Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as a promising therapeutic approach for inflammatory bowel disease (IBD) due to their anti-inflammatory properties, immune modulation, and tissue regeneration potential. However, challenges in optimizing their production, efficacy, and understanding their therapeutic mechanisms remain. MSC-EVs, particularly those derived from bone marrow and umbilical mesenchymal stem cells, have shown significant therapeutic potential in both preclinical and clinical studies. Although the advantages of MSC-EVs over traditional therapies, such as low immunogenicity and non-invasive administration, limitations in their targeting capabilities and stability in fibrotic tissues impede full clinical translation. This review succinctly outlines a comparative analysis of MSC-EVs derived from various sources, such as bone marrow, adipose tissue, perinatal tissues, dental tissues, olfactory mucosa, and hair follicles in IBD treatment. Additionally, the applications of bioengineered MSC-EVs, including their use as nanodrug carriers and in targeted therapies, are discussed, with an emphasis on the future potential of integrating MSC-EVs with biomaterials like hydrogels. Finally, the current challenges and potential solutions for translating MSC-EVs from bench to bedside are discussed. This review aims to elucidate the therapeutic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansInflammatory Bowel DiseasesExtracellular VesiclesMesenchymal Stem CellsAnimalsMesenchymal Stem Cell TransplantationBioengineering
Hair & ScalpChronic InflammationImmune Modulation
View on PubMedDOI

Related research